Health ❯ Healthcare ❯ Pharmaceuticals ❯ Clinical Trials

Atopic Dermatitis

Sanofi Pushes Amlitelimab Toward 2026 Filings After Mixed Phase 3 Readouts

The company is targeting second-half 2026 global submissions after reporting a consistent safety profile.

Sanofi’s Amlitelimab Meets Phase 3 Goals in Eczema as Shares Fall on Tepid Efficacy